转铁蛋白受体在子宫颈癌中的表达及其临床意义

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (2508 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the potential correlation between TFRC (transferrin receptor) gene expression and the development of cervical cancer. Methods: The expression of TFRC and TfR1 were detected in 96 cases of cervical cancer patients and 30 cases of normal controls with immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) method. At the same time, TCGA database was used to analyze the data of patients with cervical cancer and the survival was analyzed with Kaplan-Meier method. Results: The expression of TfR1 was positive in 50 cases of cervical carcinoma, and the intensity of staining increased with the increase of cervical cancer patients. Compared with normal cervical tissues, cervical carcinoma in stage II and III was significantly enhanced (P<0.001). The expression of TfR1 was related to the FIGO stage, the degree of tumor differentiation and the presence of metastasis (P<0.05). However, it has nothing to do with the age of patients with cervical cancer (P>0.05). The gene expression of TFRC was observed in both cervical cancer cases and normal cervical tissues. There was correlation between TFRC expression and histological grades (P<0.001). The expression of TFRC in phase II and phase III was significantly higher than that in early stage of cervical cancer. According to Kaplan-Meier survival analysis, the level of TFRC gene expression was associated with overall survival rate of cervical cancer patients (P<0.001). The stronger expression of TFRC gene, the lower the overall survival rate of patients with cervical cancer. Conclusion: TFRC may be involved in the process of development of cervical cancer and related with the prognosis of patients with cervical cancer.

Key words： receptor, transferrin uterine cervical neoplasms prognosis

Received: 19 August 2016

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Yuanyuan
	WANG Binqiao
	LAN Xiaoxiao
	WU Xueqing.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2017/V47/I4/254

[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] 邓立峰, 张永胜, 崔红霞, 等. 子宫颈鳞状细胞癌组织中MCT4的表达及其临床病理学意义[J]. 临床与实验病理学杂志, 2015, 1(3): 29-31.
[3] XU G, LIU R, ZAK O, et al. Structural allostery and binding of the transferrin-receptor complex[J]. Mol Cell Proteomicse, 2005, 4(12): 1959-1967.
[4] 邓太海, 陈舒华. 转铁蛋白受体与肿瘤疾病的关系[J]. 海南医学, 2011, 22(5): 137-139.
[5] O’DONNELL K A, YU D, ZELLER K L, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis[J]. Mol Cell Biol, 2006, 26(6): 2373-2386.
[6] WADA S, NOGU CHI T, TAKENO S, et al. PIK3CA and TFRC located in 3q are new prognostic factors in esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2006, 13(7): 961-966.
[7] 张莉, 徐维平, 苏育德, 等. 转铁蛋白-转铁蛋白受体在肿瘤主动靶向治疗中的应用[J]. 中国药业, 2012, 21(5): 1-3.
[8] SONG J Y, LEE J K, LEE N W, et al. Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer[J]. Int J Gynecol Cancer, 2008, 18(5): 1051-1059.
[9] ANDERSSON S, MINTS M, GYLLENSTEN U, et al. Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study[J]. Oncol Lett, 2014, 8(4): 1528-1532.
[10] GOSWAMI T, ANDREWS N C. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing [J]. J Biol Chem, 2006, 281(39): 28494-28498.
[11] OLIVEIRA F, ROCHA S, FERNANDES R. Iron metabolism: from health to disease[J]. J Clin Lab Anal, 2014, 28(3): 210-218.
[12] MASTROBERRARDINO P G, HOFFMAN E K, HOROW-ITS M P, et al. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson’s disease[J]. Neurobiol Dis, 2009, 34(3): 417-431.
[13] DANIELS T R, DELGADO T, RODRGUEZ J A, et al. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer[J]. J Clin Immunol,2006, 121(2): 144-158.
[14] PRUTKI M, POLJAK BLAZI M, JAKOPOVIC M, et al. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer[J]. Cancer Lett, 2006, 238(2): 188-196.
[15] 葛倩倩, 陈秀芹, 郭琦, 等. CD146和TfR1在上皮性卵巢癌中的表达及临床意义[J]. 西安交通大学学报, 2017, 38(1):104-107.
[16] MANI S A, GUO W, LIAO M J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133(4): 704-715.
[17] HILDESHEIM A, GONZALEZ P, KREIMER A R, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment[J]. Am J Obstet Gynecol, 2016, 215(2): 212. e1-e15.
[18] LLOYD J M, O’DOWD T, Driver M, et al. Demonstration of an epitope of the transferrin receptor in human cervical epithelium—a potentially useful cell marker[J]. J Clin Pathol, 1984,37(2): 131-135.
[19] 石春勤, 姜羽凤, 胡巧红. 受体介导的主动靶向给药载体研究进展[J]. 中国药学杂志, 2011, 46(21): 1617-1621.